Abstract
Elsamitrucin (BMY-28090) a novel fermentation product has demonstrated pre-clinical anti-tumour activity against a number of cell lines. The dose limiting toxicity in phase I studies was a reversible increase in hepatic transaminase. This study was initiated to determine the activity of elsamitrucin in patients with previously untreated, bi-dimensionally measurable, cytologically or histologically proven, non-small cell lung cancer who were not curable by surgery. Elsamitrucin at a dose of 25 mg/m2 was administered intravenously over 5–10 min weekly for a minimum of 6 weeks. Seventeen patients were entered on study, 15 were evaluable for toxicity and 14 evaluable for response. No responses were documented in the 14 patients evaluable for response. Both hematological and non-hematological toxicities were mild to moderate in severity. The commonest being nausea, vomiting, lethargy and local skin reactions at the site of the infusion. These results indicate that elsamitrucin when given in this dose and schedule to patients with surgically incurable non-small cell lung cancer has no activity.
Similar content being viewed by others
References
Tanis BC, Vermorken JB, ten Bokkel Huinink WW, van der Vijgh WJF, Klein J, McDaniel C, Pinedo HM: Phase I study of elsamicin (BMY-28090) (abstract) Proc Am Soc Clin One 9(276):71, 1990
Raber M, Amato R, Sumrall C, Schacter L: Phase I clinical trial of elsamitrucin (abstract) Proc Am Assoc Can Res 31 (1058):178, 1990
La Creta FP, Langer C, Walczak J, Tinsley P, Schacter L, Comis RL, Ozols RF, O'Dwyer PJ: Phase I/pharmacokinetic study of elsamitrucin (BMY-28090, NSC 369 327) in patients with advanced cancer (abstract) Proc Am Soc Clin Onc 9(279):72, 1990
Author information
Authors and Affiliations
Additional information
A National Cancer Institute of Cancer Clinical Trials Group study sponsored by Bristol-Myers-Squibb Co. Walingford, CT.
Rights and permissions
About this article
Cite this article
Goss, G., Letendre, F., Stewart, D. et al. Phase II study of elsamitrucin in non-small cell lung cancer. Invest New Drugs 12, 315–317 (1994). https://doi.org/10.1007/BF00873046
Issue Date:
DOI: https://doi.org/10.1007/BF00873046